ClinicalTrials.gg
RecruitingNCT07859852B-RAPIDUpdated Oct 8, 2026

Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test

An observational study in Blood Stream Infection, Blood Stream Infections and Sepsis, sponsored by Deepull Diagnostics S.L.. Recruiting at 20 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Deepull Diagnostics S.L. · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 8, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.

Planned enrollment
32nd of 204
1,500 · median 183
Started
2026
with 28 others
Observational
204 of 517
37 open now
Primary completion
2027-04
later than 43 of 98 live
Registered
516th of 517
by date

Among the 517 studies in Sepsis with a site in United States, this one is the 32nd largest by planned enrollment of the 204 observational ones that give a count, is one of 29 that started in 2026, is one of 204 observational ones, reaches primary completion later than 43 of the 98 other live ones, and was the 516th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Sepsis with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the clinical performance of the UllCORE Bloodstream Infection (BSI) Test, an investigational molecular diagnostic test intended to detect microorganisms and selected antimicrobial resistance markers directly from whole blood in patients with suspected bloodstream infection or sepsis.

Participants enrolled in the study will have blood collected at the same time as blood samples obtained for standard-of-care blood culture testing. Study blood samples will be tested using the UllCORE BSI Test either as fresh samples or after frozen storage, according to the study protocol.

The results of the UllCORE BSI Test will be compared with standard-of-care microbiology results and, when applicable, additional testing methods to assess the diagnostic performance of the investigational test.

The UllCORE BSI Test results will not be used to guide patient care and will not be provided to treating healthcare professionals for clinical decision-making. Participation in the study will therefore not change the standard medical care received by participants.

03

Conditions studied

  • Blood Stream Infection
  • Blood Stream Infections
  • Sepsis
  • Fungemia
  • Bacteremia

Keywords

  • Bloodstream infection
  • Blood culture
  • Molecular diagnostics
  • Molecular diagnostic testing
  • Whole blood
  • Pathogen detection
  • Antimicrobial resistance markers
  • Rapid diagnostic testing
  • Sepsis diagnosis
  • Direct-from-blood testing
  • Multiplex polymerase chain reaction
  • UllCORE BSI Test
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will consist of patients with suspected bloodstream infection (BSI) or sepsis who are undergoing standard-of-care blood culture testing. Participants will be recruited from Emergency Departments and Intensive Care Units.

Eligible patients will be identified based on clinical signs and symptoms consistent with suspected BSI or sepsis, such as fever, elevated inflammatory markers, hypotension, or other clinical findings prompting blood culture collection. Participants meeting the eligibility criteria will be enrolled prospectively and consecutively, without preference for specific demographic or clinical characteristics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any age (where the remaining criteria can be safely fulfilled)
  • Ability to provide consent/assent in accordance with Institutional Review Board (IRB)/Ethics Committee (EC) determinations
  • The patient is presenting with signs and symptoms of suspected bloodstream infection (BSI) or fulfils the criteria for the hospital sepsis protocol.

Planned blood culture collection and laboratory analysis as per standard of care (SOC).

  • Patient is able and an appropriate candidate to be able to collect 2 K2 ethylenediaminetetraacetic acid (EDTA) tubes of whole blood.

Exclusion criteria

Exclusion Criteria:

  • Unable to collect UllCORE BSI Test samples from the same venipuncture as blood culture (BC) samples
  • Patient was previously enrolled in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants with Suspected Bloodstream Infection or Sepsis

    Participants with suspected bloodstream infection or sepsis whose prospectively collected whole-blood specimens are either tested fresh using the investigational UllCORE Bloodstream Infection (BSI) Test or stored frozen before subsequent testing. UllCORE BSI Test results will be compared with standard-of-care microbiology results and will not be used for clinical decision-making.

    Diagnostic Test: UllCORE BSI Test

Interventions

  • Diagnostic testUllCORE BSI Test

    The UllCORE Bloodstream Infection (BSI) Test is an investigational molecular diagnostic test designed to detect microorganisms and selected antimicrobial resistance markers directly from whole blood. In this study, prospectively collected whole blood specimens will be tested either fresh or after frozen storage, according to the study protocol. UllCORE BSI Test results will be compared with standard-of-care microbiology results and will not be used for clinical decision-making.

06

What researchers measure

Primary outcomes

  1. Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test Assessed by Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)

    Clinical performance of the UllCORE Bloodstream Infection (BSI) Test will be assessed using positive percent agreement (PPA) and negative percent agreement (NPA) compared with standard-of-care microbiological methods, as applicable. Performance will be evaluated for the microorganisms and antimicrobial resistance markers included in the test panel.

    Time frame: From specimen collection through completion of investigational and comparator testing, up to 365 days after specimen collection.

07

Study locations

1 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Apr 2027, 7 months after the start.

Of 52 industry-sponsored observational studies under Sepsis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 44. This study's planned 7 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Sep 21, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAbility to provide consent/assent in accordance with Institutional Review Board (IRB)/Ethics Committee (EC) determinations
  • EditedPlanned blood culture collection and laboratory analysis as per standard of care (SOC).
  • EditedPatient is able and an appropriate candidate to be able to collect 2 K2 ethylenediaminetetraacetic acid (EDTA) tubes of whole blood.
Exclusion criteria
  • EditedUnable to collect UllCORE BSI Test samples from the same venipuncture as blood culture (BC) samples
Oct 8, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedClinical Performance of the UllCORE ID Bloodstream Infection (BSI) Test Assessed by Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)Time frame: From specimen collection through completion of investigational and comparator testing, up to 365 days after specimen collection.
Oct 8, 2026
Title
Evaluation of Diagnostic Accuracy and Clinical Performance of the UIICORE UllCORE Bloodstream Infection (BSI) Test
Oct 8, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 8, 2026
    Eligibility 3 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAbility to provide consent/assent in accordance with Institutional Review Board (IRB)/Ethics Committee (EC) determinations
    • EditedPlanned blood culture collection and laboratory analysis as per standard of care (SOC).
    • EditedPatient is able and an appropriate candidate to be able to collect 2 K2 ethylenediaminetetraacetic acid (EDTA) tubes of whole blood.
    Exclusion criteria
    • EditedUnable to collect UllCORE BSI Test samples from the same venipuncture as blood culture (BC) samples
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedClinical Performance of the UllCORE ID Bloodstream Infection (BSI) Test Assessed by Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)Time frame: From specimen collection through completion of investigational and comparator testing, up to 365 days after specimen collection.
    Title Evaluation of Diagnostic Accuracy and Clinical Performance of the UIICORE UllCORE Bloodstream Infection (BSI) Test
    + 4 other changes: verification date, description, design details and arm descriptions
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859852
Lead sponsor
Deepull Diagnostics S.L.
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Sep 21, 2026
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Roger Canton
Contact
rcanton@deepull.com
936553530 ext. +34

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion